235.35 -0.01 (-0.00%)
After hours: 7:30PM EDT
|Bid||231.20 x 100|
|Ask||253.78 x 100|
|Day's Range||235.32 - 244.26|
|52 Week Range||167.16 - 256.64|
|PE Ratio (TTM)||47.84|
|Earnings Date||Apr 23, 2018 - Apr 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||257.61|
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Illumina, Inc. . Illumina is a San Diego, CA-based company that provides sequencing and array-based solutions for genetic analysis.
Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating.
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory. The software has the ability to support data integrity, process adherence, and regulatory compliance. The system provides enhanced data software capabilities like sample management and data archiving as compared to the traditional CDS (chromatography data systems).
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
Illumina, Inc. announced today the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer , starting March 26, 2018. In his new role, Dr.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $16.76 billion.
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services, expand in the research market, and leverage its monitoring platform in new markets. In order to increase the demand for its portfolio of outpatient cardiac monitoring solutions, BioTelemetry is focusing on educating cardiologists, electrophysiologists, and neurologists on the benefits of using mobile cardiac telemetry for arrhythmia monitoring while stressing the increased diagnostic yield and ability to deliver more effective treatments.
BioTelemetry (BEAT) provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. In July 2017, BioTelemetry acquired LifeWatch, a supplier of mobile cardiac monitoring solutions. The acquisition is expected to help BioTelemetry create a comprehensive connected healthcare platform and deliver solutions in the market more effectively.
March 6 (Reuters) - Anhui Anke Biotechnology Group Co Ltd : * SAYS ITS UNIT OBTAINS EXCLUSIVE DISTRIBUTION RIGHTS IN CHINA FOR PRODUCTS OF VEROGEN, U.S. COMPANY JOINTLY SET UP BY U.S. FIRMS ILLUMINA AND ...
Helix, a personal genomics company that genetic testing giant Illumina Inc. spun out in 2015, said on Thursday it is raising $200 million to further develop its online marketplace for DNA tests. The San Carlos company partners with 50 companies and medical centers that offer genetic test kits to consumers on its online marketplace.
Welcome to the future... where startups are willing to customize everything from a diet regimen to a workout plan, or family planning to personal fashion based on an individual's genetic code. Angling to be the go-to marketplace for these gene-based businesses, Helix, the spin out from genetic testing research and technology giant Illumina, has held a first close on a planned $200 million funding round led by new investor DFJ Growth. Since its $100 million spin out in August 2015, the company has seen companies list about 35 products on its marketplace and expects to have about 70 to 100 products listed by the end of the year, according to chief executive Robin Thurston.
Mérieux Développement and Paladin Capital Group announced the completion of a $55.5 million Series C funding into Inscripta, a leading gene-editing technology company, based in Boulder, CO and Pleasanton, CA. Additional participants include all existing investors: Venrock, Foresite, Spruce, and NanoDimension. The new funding comes on the heels of the company's release of its first CRISPR enzyme (MAD7), and will accelerate Inscripta's development of gene-editing tools, including instruments, reagents, and software, and grow the company's expert team.
Illumina, Inc. today announced that its executives will be speaking at the following investor conference, and invites investors to participate via webcast.
Genomics pioneer and biotech industry leader Illumina may be sequencing a new breakout as it codevelops next-generation cancer treatments for the Chinese market.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $979 million.